---
schema_version: "secwatch.filing_event.v1"
accession: "0001472375-25-000130"
form_type: "8-K"
ticker: "RGPX"
cik: "0001357878"
company_name: "REGENEREX PHARMA, INC."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:59:24.707787+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Regenerex Pharma changes fiscal year end from March 31 to December 31

## Summary
- Board approved fiscal year change effective September 22, 2025.
- New fiscal year end will be December 31, replacing March 31.
- Transition report on Form 10-K for April 1, 2025 to December 31, 2025 to be filed.
- No other amendments to bylaws or articles were disclosed.

## SEC filing metadata
- accession: 0001472375-25-000130
- form_type: 8-K
- ticker: RGPX
- cik: 0001357878
- company_name: REGENEREX PHARMA, INC.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357878/000147237525000130/0001472375-25-000130-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357878/000147237525000130/ixform8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001472375-25-000130
- JSON: https://secwatch.observer/filing/0001472375-25-000130.json
- Plain text: https://secwatch.observer/filing/0001472375-25-000130.txt

## Key facts
- Governance Changes
  REGENEREX PHARMA, INC.: Changed fiscal year end from March 31 to December 31 (effective 2025-09-22).
  - Change: fiscal year change
  - Effective: 2025-09-22
  source text: the Board of Directors (the “Board”) of Regenerex Pharma, Inc. (the “Company”) approved a change to the Company’s fiscal year end from March 31 to December 31
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357878/000147237525000130/0001472375-25-000130-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.